secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amylyx Pharmaceuticals, Inc. (AMLX)
CIK:        0001658551
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0000950170-22-016880
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amylyx reports Q2 net loss $54.1M; ALBRIOZA launched in Canada; FDA PDUFA Sept 29
--------------------------------------------------------------------------------

- Net loss of $54.1M ($0.93/sh) vs $21.9M ($3.41/sh) in Q2 2021; cash $206.7M at quarter end.
- ALBRIOZA (AMX0035) commercially launched in Canada on July 29, 2022 – first product launch.
- FDA Advisory Committee meeting for ALS NDA scheduled Sept 7, 2022; PDUFA action date Sept 29, 2022.
- EU MAA under review; EMA decision expected first half 2023, with launch prep underway.
- R&D expense $24.3M (up from $10.9M); G&A expense $30.0M (up from $7.7M) driven by commercial readiness.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658551/000095017022016880/0000950170-22-016880-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658551/000095017022016880/amlx-20220811.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-016880

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer